{"id":68294,"date":"2026-06-16T14:19:48","date_gmt":"2026-06-16T06:19:48","guid":{"rendered":"https:\/\/flcube.com\/?p=68294"},"modified":"2026-06-16T14:19:49","modified_gmt":"2026-06-16T06:19:49","slug":"lynk-pharmaceuticals-files-for-hong-kong-ipo-autoimmune-pipeline-led-by-jak-inhibitors-and-novel-protein-degraders","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68294","title":{"rendered":"Lynk Pharmaceuticals Files for Hong Kong IPO \u2013 Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Lynk Pharmaceuticals Co., Ltd.<\/strong> announced it has <strong>published its prospectus<\/strong> and formally <strong>applied for listing on the Hong Kong Stock Exchange<\/strong>, positioning itself as an innovative biopharmaceutical company focused on <strong>small molecule inhibitors for autoimmune and inflammatory diseases<\/strong>. Founded in 2017, the company has built a diversified pipeline featuring two core clinical-stage products and seven additional candidates spanning novel therapeutic modalities.<\/p>\n\n\n\n<h2 id=\"h-company-profile-amp-pipeline-overview\" class=\"wp-block-heading\">Company Profile &amp; Pipeline Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Founded<\/strong><\/td><td>2017<\/td><\/tr><tr><td><strong>Headquarters<\/strong><\/td><td>Shanghai, China<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Autoimmune and inflammatory diseases<\/td><\/tr><tr><td><strong>Core Products<\/strong><\/td><td>LNK01001 (oral JAK1 inhibitor); LNK01004 (topical pan-JAK inhibitor)<\/td><\/tr><tr><td><strong>Pipeline Depth<\/strong><\/td><td>9 total candidates (2 core + 7 additional)<\/td><\/tr><tr><td><strong>Technology Platforms<\/strong><\/td><td>Selective kinase inhibition; PROTAC protein degradation; molecular glue degraders<\/td><\/tr><tr><td><strong>Listing Venue<\/strong><\/td><td>Hong Kong Stock Exchange (application pending)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-core-product-portfolio\" class=\"wp-block-heading\">Core Product Portfolio<\/h2>\n\n\n\n<h3 id=\"h-lnk01001-oral-second-generation-selective-jak1-inhibitor\" class=\"wp-block-heading\">LNK01001 \u2013 Oral Second-Generation Selective JAK1 Inhibitor<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indications:<\/strong> Moderate-to-severe rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, and vitiligo<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Enhanced selectivity profile compared to first-generation JAK inhibitors, potentially improving safety while maintaining efficacy<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Advanced clinical development with multiple Phase II\/III trials ongoing<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-lnk01004-topical-soft-pan-jak-inhibitor\" class=\"wp-block-heading\">LNK01004 \u2013 Topical Soft Pan-JAK Inhibitor<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication:<\/strong> Mild-to-moderate atopic dermatitis and other inflammatory skin diseases<\/li>\n\n\n\n<li><strong>Key Innovation:<\/strong> High local JAK inhibition with minimal systemic exposure, enabling safe long-term topical treatment<\/li>\n\n\n\n<li><strong>Therapeutic Advantage:<\/strong> Addresses unmet need for chronic inflammatory skin conditions requiring sustained therapy without systemic side effects<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-innovative-pipeline-candidates\" class=\"wp-block-heading\">Innovative Pipeline Candidates<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Candidate<\/th><th>Mechanism<\/th><th>Target Indication<\/th><th>Development Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>LNK01006<\/strong><\/td><td>Centrally penetrant allosteric TYK2 inhibitor<\/td><td>CNS-inflammatory disorders<\/td><td>Clinical<\/td><\/tr><tr><td><strong>LNK009<\/strong><\/td><td>STAT6 PROTAC degrader<\/td><td>Allergic inflammation, asthma<\/td><td>Preclinical<\/td><\/tr><tr><td><strong>LNK011<\/strong><\/td><td>VAV1 molecular glue degrader<\/td><td>Autoimmune disorders<\/td><td>Preclinical<\/td><\/tr><tr><td><strong>LNK013<\/strong><\/td><td>IRAK4 PROTAC degrader<\/td><td>Inflammatory diseases<\/td><td>Preclinical<\/td><\/tr><tr><td><strong>LNK014<\/strong><\/td><td>NEK7 molecular glue degrader<\/td><td>Autoimmune conditions<\/td><td>Preclinical<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The pipeline demonstrates Lynk&#8217;s strategic evolution from traditional kinase inhibition toward cutting-edge protein degradation technologies, positioning the company at the forefront of next-generation autoimmune therapeutics.<\/p>\n\n\n\n<h2 id=\"h-market-position-amp-competitive-landscape\" class=\"wp-block-heading\">Market Position &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Autoimmune Market Opportunity:<\/strong> Global autoimmune disease therapeutics market projected to reach <strong>US$180 billion by 2030<\/strong>, growing at <strong>8.5% CAGR<\/strong><\/li>\n\n\n\n<li><strong>JAK Inhibitor Segment:<\/strong> Despite safety concerns with first-generation agents, selective JAK1 inhibitors continue to show strong commercial potential with improved risk-benefit profiles<\/li>\n\n\n\n<li><strong>Protein Degradation Leadership:<\/strong> Lynk represents one of China&#8217;s most advanced companies in applying PROTAC and molecular glue technologies to autoimmune indications, a relatively underexplored application area globally<\/li>\n\n\n\n<li><strong>Geographic Strategy:<\/strong> Initial focus on China&#8217;s large autoimmune patient population (estimated 100+ million patients) with plans for global expansion through partnerships<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-outlook-amp-use-of-proceeds\" class=\"wp-block-heading\">Financial Outlook &amp; Use of Proceeds<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">While detailed financials will be disclosed in the final prospectus, industry analysts estimate:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2025 Revenue:<\/strong> Primarily from partnerships and licensing (minimal product revenue)<\/li>\n\n\n\n<li><strong>Cash Runway:<\/strong> Sufficient to advance LNK01001 through regulatory approval and LNK01004 to Phase III completion<\/li>\n\n\n\n<li><strong>Primary Use of IPO Proceeds:<\/strong><\/li>\n\n\n\n<li>40% \u2013 Late-stage clinical development of core products<\/li>\n\n\n\n<li>25% \u2013 Expansion of protein degradation platform capabilities<\/li>\n\n\n\n<li>20% \u2013 International clinical trial initiation and regulatory filings<\/li>\n\n\n\n<li>15% \u2013 Working capital and general corporate purposes<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The Hong Kong listing would provide Lynk with enhanced access to international capital markets while maintaining its strategic focus on developing differentiated therapies for high-burden autoimmune and inflammatory conditions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Lynk Pharmaceuticals&#8217; IPO application, clinical development timelines, and business strategy. Actual results may differ due to risks including regulatory approval of the listing, clinical trial outcomes, competitive dynamics, and execution of the company&#8217;s growth strategy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/sehk26061501862_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26061501862_c.\"><\/object><a id=\"wp-block-file--media-855fb8c6-0e26-435d-b92f-91a553d9d9ec\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/sehk26061501862_c.pdf\">sehk26061501862_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/sehk26061501862_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-855fb8c6-0e26-435d-b92f-91a553d9d9ec\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lynk Pharmaceuticals Co., Ltd. announced it has published its prospectus and formally applied for listing&#8230;<\/p>\n","protected":false},"author":1,"featured_media":68297,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[72,1351],"class_list":["post-68294","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ipo","tag-lynk-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lynk Pharmaceuticals Files for Hong Kong IPO \u2013 Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lynk Pharmaceuticals Co., Ltd. announced it has published its prospectus and formally applied for listing on the Hong Kong Stock Exchange, positioning itself as an innovative biopharmaceutical company focused on small molecule inhibitors for autoimmune and inflammatory diseases. Founded in 2017, the company has built a diversified pipeline featuring two core clinical-stage products and seven additional candidates spanning novel therapeutic modalities.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68294\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lynk Pharmaceuticals Files for Hong Kong IPO \u2013 Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders\" \/>\n<meta property=\"og:description\" content=\"Lynk Pharmaceuticals Co., Ltd. announced it has published its prospectus and formally applied for listing on the Hong Kong Stock Exchange, positioning itself as an innovative biopharmaceutical company focused on small molecule inhibitors for autoimmune and inflammatory diseases. Founded in 2017, the company has built a diversified pipeline featuring two core clinical-stage products and seven additional candidates spanning novel therapeutic modalities.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68294\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-16T06:19:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-16T06:19:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1604.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68294#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68294\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lynk Pharmaceuticals Files for Hong Kong IPO \u2013 Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders\",\"datePublished\":\"2026-06-16T06:19:48+00:00\",\"dateModified\":\"2026-06-16T06:19:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68294\"},\"wordCount\":543,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68294#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1604.webp\",\"keywords\":[\"IPO\",\"Lynk Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68294#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68294\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68294\",\"name\":\"Lynk Pharmaceuticals Files for Hong Kong IPO \u2013 Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68294#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68294#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1604.webp\",\"datePublished\":\"2026-06-16T06:19:48+00:00\",\"dateModified\":\"2026-06-16T06:19:49+00:00\",\"description\":\"Lynk Pharmaceuticals Co., Ltd. announced it has published its prospectus and formally applied for listing on the Hong Kong Stock Exchange, positioning itself as an innovative biopharmaceutical company focused on small molecule inhibitors for autoimmune and inflammatory diseases. Founded in 2017, the company has built a diversified pipeline featuring two core clinical-stage products and seven additional candidates spanning novel therapeutic modalities.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68294#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68294\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68294#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1604.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1604.webp\",\"width\":1080,\"height\":608,\"caption\":\"Lynk Pharmaceuticals Files for Hong Kong IPO \u2013 Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68294#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lynk Pharmaceuticals Files for Hong Kong IPO \u2013 Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lynk Pharmaceuticals Files for Hong Kong IPO \u2013 Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders - Insight, China&#039;s Pharmaceutical Industry","description":"Lynk Pharmaceuticals Co., Ltd. announced it has published its prospectus and formally applied for listing on the Hong Kong Stock Exchange, positioning itself as an innovative biopharmaceutical company focused on small molecule inhibitors for autoimmune and inflammatory diseases. Founded in 2017, the company has built a diversified pipeline featuring two core clinical-stage products and seven additional candidates spanning novel therapeutic modalities.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68294","og_locale":"en_US","og_type":"article","og_title":"Lynk Pharmaceuticals Files for Hong Kong IPO \u2013 Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders","og_description":"Lynk Pharmaceuticals Co., Ltd. announced it has published its prospectus and formally applied for listing on the Hong Kong Stock Exchange, positioning itself as an innovative biopharmaceutical company focused on small molecule inhibitors for autoimmune and inflammatory diseases. Founded in 2017, the company has built a diversified pipeline featuring two core clinical-stage products and seven additional candidates spanning novel therapeutic modalities.","og_url":"https:\/\/flcube.com\/?p=68294","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-16T06:19:48+00:00","article_modified_time":"2026-06-16T06:19:49+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1604.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68294#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68294"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lynk Pharmaceuticals Files for Hong Kong IPO \u2013 Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders","datePublished":"2026-06-16T06:19:48+00:00","dateModified":"2026-06-16T06:19:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68294"},"wordCount":543,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=68294#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1604.webp","keywords":["IPO","Lynk Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68294#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68294","url":"https:\/\/flcube.com\/?p=68294","name":"Lynk Pharmaceuticals Files for Hong Kong IPO \u2013 Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=68294#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=68294#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1604.webp","datePublished":"2026-06-16T06:19:48+00:00","dateModified":"2026-06-16T06:19:49+00:00","description":"Lynk Pharmaceuticals Co., Ltd. announced it has published its prospectus and formally applied for listing on the Hong Kong Stock Exchange, positioning itself as an innovative biopharmaceutical company focused on small molecule inhibitors for autoimmune and inflammatory diseases. Founded in 2017, the company has built a diversified pipeline featuring two core clinical-stage products and seven additional candidates spanning novel therapeutic modalities.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68294#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68294"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=68294#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1604.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1604.webp","width":1080,"height":608,"caption":"Lynk Pharmaceuticals Files for Hong Kong IPO \u2013 Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68294#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lynk Pharmaceuticals Files for Hong Kong IPO \u2013 Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1604.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68294"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68294\/revisions"}],"predecessor-version":[{"id":68298,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68294\/revisions\/68298"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/68297"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}